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ABSTRACT
LAM is a rare multisystem disease primarily involving lungs. There is an average lag time of 4
years from the onset of symptoms till the diagnosis is made. Current methods of diagnosis are 
invasive and associated with a lot of limitations. Clinically, interstitial lung disease (ILD) 
resembles LAM and there are no methods available that are less invasive, and yield quicker 
results, in order to differentiate the two. The aims of this study are to identify potential 
biomarkers for LAM diagnosis and also determine its clinical severity just by using a simple 
blood test.  
This pilot study was conducted to investigate and validate the differential expression of 10 
proteins in the blood of patients suffering from lymphangioleiomyomatosis (LAM) as compared 
to interstitial lung disease (ILD) (idiopathic pulmonary fibrosis) and normal healthy subjects in 
order to determine if any of the proteins could serve as a potential biomarker for the early 
diagnosis of LAM. The 10 proteins selected for study were lipopolysaccharide binding protein 
(LBP), Fetuin-B, apolipoprotein A1 (APO A1), apolipoprotein A4 (APO A4), heparin cofactor 2,
phospholipid transfer protein (PLTP), plasma serine protease inhibitor 5 (SERPIN A5 gene 
product), N-acetylmuramoyl-L-alanine amidase (PGLYRP2), sex hormone binding globulin 
(SHBG) and Talin 1. These proteins were selected on the basis of a proteomics study (LC/MS) 
which showed altered expression levels (either increased or decreased) of these proteins in sera 
from LAM patients, as compared to normal controls.  
Validation of differential expression of the selected protein targets was carried out using either 
ELISA or western analysis using sera from LAM patients (n=10), ILD patients (n=10) and 
normal age matched individuals (n=10). Blood samples were obtained from and a blood biobank 
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established. The expression of each of the 10 candidate proteins was validated in all three sample 
groups and data obtained was analysed to establish the statistical significance of any detected 
protein level alterations.  
The validation experiments carried out showed that Fetuin-B was significantly decreased in LAM 
patient sera as compared to ILD patients (p=0.023). Heparin cofactor 2 was significantly 
decreased in LAM patients as compared to normal healthy individuals (p=0.030). PGLYRP2 was 
significantly reduced in LAM as compared to ILD patients (p=0.00047) and normal healthy 
human subjects (p=0.0061). Further, clinical severity of disease (ILD and LAM) was also 
correlated with the protein level differences observed. Correlation analysis showed that, in LAM, 
levels of heparin cofactor 2, PGLYRP2 and Fetuin-B decrease with increasing severity of the 
disease. In ILD, levels of APO A4 were shown to be decreased with increasing disease severity 
in ILD, while plasma serine protease inhibitor levels were increased with the increasing disease 
severity.  
This study data identified some novel potential biomarkers for diagnosing LAM by 
differentiating it from other similar diseases and normal individuals. These include Fetuin-B, 
Heparin cofactor 2 and PGLYRP2. Additionally, some potential protein biomarkers of severity 
were also identified for LAM and ILD. These potential biomarkers may, in future be used for 
diagnostic purposes in LAM and also for determining stage/severity of LAM and ILD.
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